4//SEC Filing
ROCAMBOLI STEPHEN 4
Accession 0001213900-21-016184
CIK 0001733413other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 8:00 PM ET
Size
12.7 KB
Accession
0001213900-21-016184
Insider Transaction Report
Form 4
ROCAMBOLI STEPHEN
Director
Transactions
- Exercise/Conversion
Common Stock
2021-03-15$5.00/sh+5,250$26,250→ 35,728 total - Sale
Common Stock
2021-03-15$16.85/sh−20,006$337,101→ 15,722 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-03-15−14,756→ 107,673 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (14,756 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2021-03-15−5,250→ 102,423 totalExercise: $5.00From: 2020-10-29Exp: 2029-10-28→ Common Stock (5,250 underlying) - Exercise/Conversion
Common Stock
2021-03-15$2.50/sh+14,756$36,890→ 30,478 total
Footnotes (3)
- [F1]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F2]23,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vest at an approximate rate of 5,750 every three months thereafter
- [F3]10,948 shares of common stock vested on October 29, 2020 and the remainder of the shares vest at an approximate rate of 2,737 every three months thereafter
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001221451
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 8:00 PM ET
- Size
- 12.7 KB